AQAI Simulation Centre Mayence optimises training in use of anaesthetics
24 September 2012
Medical products supplier Baxter is co-operating with the AQAI Simulation Centre to train new customers' medical and nursing staff in the Middle East to use its anaesthetic quickly and without risk for patients.
Baxter produces pharmaceuticals, including anaesthetics such as Suprane (Desflurane, USP) and Forane (Isoflurane, USP) and aims at expand its market share in the Middle East, in particular with regard to Desflurane.
AQAI configured simulators, the equipment landscape, and sophisticated scenarios which represent the application context in a realistic manner. The technology encompasses heating, vaporization, as well as real washing in and out of the anaesthetic. Barriers which needed to be overcome included climate challenges: the boiling point of Desflurane is approximately 23C, a temperature that is frequently exceeded in the Middle East.
This simulation configuration was implemented at the University Hospital in Riyadh, Saudi Arabia. AQAI has made similar installations in the UK, in Russia, Egypt, and South Africa, where they provided significant support for product roll-out and today serve in routine further education in anaesthetics application.
First simulation course a success
In mid May 2012 Baxter organized the first simulation-based training for Desflurane in Saudi Arabia. “We are highly satisfied with how the scenarios turned out. They worked without problems and in accordance with our expectations, and they produced the desired know-how for participants”, said Ala Asi who is in charge of Baxter sales.
“We will focus even more on the application of Suprane in the future; and we plan to develop scenarios which help communicate in detail the differences between handling Suprane in comparison with Sevoflurane [a competitive product] and Isoflurane”.
Baxter will collaborate with AQAI on these projects. The next simulation-based training for anaesthetics in Riyadh is scheduled for late September.
“Our innovative approach supports manufacturers and care providers in ensuring safe application of new products by the staff — without putting life, and quality of life, of patients at risk”, underlines Prof. Dr. med. Wolfgang Heinrichs, anesthetist and Director of the AQAI Simulation Center. According to the expert, the potentials for the use of simulation in the context of the roll-out of many other pharmaceuticals and medtech products are huge.